Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
Status: Enrolling
Updated:  8/30/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
Status: Enrolling
Updated: 8/30/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Dermatology Research Associate
mi
from
Los Angeles, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Dermatology Research Associate
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Stanford University
mi
from
Palo Alto, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
California Pacific Medical Center Research Institute
mi
from
Santa Rosa, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
California Pacific Medical Center Research Institute
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Advanced Derm & Cosmetic Surg
mi
from
Ormond Beach, FL
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Advanced Derm & Cosmetic Surg
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Skin and Cancer Associates and the Center for Cosmetic Enhancement
mi
from
Plantation, FL
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Skin and Cancer Associates and the Center for Cosmetic Enhancement
mi
from
Plantation, FL
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Emory University Clinic
mi
from
Atlanta, GA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Emory University Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Laser & Skin Surgery Center of Indiana
mi
from
Carmel, IN
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Laser & Skin Surgery Center of Indiana
mi
from
Carmel, IN
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Beverly Hospital;Oncology Center Pharmacy
mi
from
Beverly, MA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Beverly Hospital;Oncology Center Pharmacy
mi
from
Beverly, MA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Saint Louis University School of Medicine; Department of Dermatology
mi
from
Saint Louis, MO
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Saint Louis University School of Medicine; Department of Dermatology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Long Island Skin Cancer and Dermatologic Surgery
mi
from
Smithtown, NY
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Long Island Skin Cancer and Dermatologic Surgery
mi
from
Smithtown, NY
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Mariwalla Dermatology
mi
from
West Islip, NY
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Mariwalla Dermatology
mi
from
West Islip, NY
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
The Skin Surgery Center
mi
from
Winston-Salem, NC
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
The Skin Surgery Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Ohio State University
mi
from
Columbus, OH
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Dermatology and Laser Center of Charleston
mi
from
Charleston, SC
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Dermatology and Laser Center of Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
LKH Innsbruck; Universitätsklinik für Dermatologie
mi
from
Innsbruck,
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
LKH Innsbruck; Universitätsklinik für Dermatologie
mi
from
Innsbruck,
Click here to add this to my saved trials
Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.
A Placebo-Controlled, Double-Blind, Bilateral Cosmetic Study With an Open Label Extension to Evaluate the Performance of a Cosmetic Product Designed to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.
Status: Enrolling
Updated:  8/30/2017
Medical Dermatology Associates of Chicago
mi
from
Chicago, IL
Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.
A Placebo-Controlled, Double-Blind, Bilateral Cosmetic Study With an Open Label Extension to Evaluate the Performance of a Cosmetic Product Designed to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.
Status: Enrolling
Updated: 8/30/2017
Medical Dermatology Associates of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma
An Open-Label Pilot Study Evaluating the Effectiveness and Tolerability of a Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma
Status: Enrolling
Updated:  9/19/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma
An Open-Label Pilot Study Evaluating the Effectiveness and Tolerability of a Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma
Status: Enrolling
Updated: 9/19/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Progressive Keratoconus or Ectasia Treatment Plan
Increasing CrossLinking of Corneal Collagen in Eyes With Progressive Keratoconus or Ectasia
Status: Enrolling
Updated:  9/27/2017
Edward Harkness Eye Institute-Columbia University Medical Center
mi
from
New York, NY
Progressive Keratoconus or Ectasia Treatment Plan
Increasing CrossLinking of Corneal Collagen in Eyes With Progressive Keratoconus or Ectasia
Status: Enrolling
Updated: 9/27/2017
Edward Harkness Eye Institute-Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
A Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Systemic Sclerosis
Status: Enrolling
Updated:  9/28/2017
Stanford University School of Medicine
mi
from
Stanford, CA
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
A Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Systemic Sclerosis
Status: Enrolling
Updated: 9/28/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Dermatology Research Associate
mi
from
Los Angeles, CA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Dermatology Research Associate
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
UCSD Division of Dermatology
mi
from
San Diego, CA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
UCSD Division of Dermatology
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Univ of Calif, San Francisco
mi
from
San Francisco, CA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Univ of Calif, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
University of Colorado Anschutz Cancer Pavilion
mi
from
Aurora, CO
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
University of Colorado Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Ameriderm Research
mi
from
Ormond Beach, FL
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Ameriderm Research
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Olympian Clinical Research
mi
from
Tampa, FL
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Olympian Clinical Research
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
University of Iowa Healthcare; Dermatology
mi
from
Iowa City, IA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
University of Iowa Healthcare; Dermatology
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Somerset Skin Centre
mi
from
Troy, MI
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Somerset Skin Centre
mi
from
Troy, MI
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Washington University-Dermatology
mi
from
Saint Louis, MO
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Washington University-Dermatology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Sadick Research Group
mi
from
New York, NY
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Sadick Research Group
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Oregon Health & Science University, Department of Dermatology
mi
from
Portland, OR
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Oregon Health & Science University, Department of Dermatology
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
University of Texas Medical School in Houston
mi
from
Houston, TX
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
University of Texas Medical School in Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Dermatology Clinical Research Center of San Antonio
mi
from
San Antonio, TX
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Dermatology Clinical Research Center of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
St George Dermatology and Skin Cancer Centre
mi
from
Kogarah,
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
St George Dermatology and Skin Cancer Centre
mi
from
Kogarah,
Click here to add this to my saved trials
Nilotinib in the Treatment of Systemic Sclerosis
Phase IIA Study of the Safety and Tolerability of the Use of Nilotinib in the Treatment of Systemic Sclerosis
Status: Enrolling
Updated:  10/2/2017
Hospital for Special Surgery
mi
from
New York, NY
Nilotinib in the Treatment of Systemic Sclerosis
Phase IIA Study of the Safety and Tolerability of the Use of Nilotinib in the Treatment of Systemic Sclerosis
Status: Enrolling
Updated: 10/2/2017
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated:  10/3/2017
Orange County Research Institute
mi
from
Anaheim, CA
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated: 10/3/2017
Orange County Research Institute
mi
from
Anaheim, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated:  10/3/2017
eStudySite
mi
from
Chula Vista, CA
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated: 10/3/2017
eStudySite
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated:  10/3/2017
T Joseph Raoof MD, Inc, Encino Research Center
mi
from
Encino, CA
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated: 10/3/2017
T Joseph Raoof MD, Inc, Encino Research Center
mi
from
Encino, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated:  10/3/2017
Dermatology Research Associates
mi
from
Los Angeles, CA
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated: 10/3/2017
Dermatology Research Associates
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated:  10/3/2017
eStudySite
mi
from
Oceanside, CA
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated: 10/3/2017
eStudySite
mi
from
Oceanside, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated:  10/3/2017
Empire Clinical Research
mi
from
Upland, CA
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated: 10/3/2017
Empire Clinical Research
mi
from
Upland, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated:  10/3/2017
Horizons Clinical Research Center, LLC
mi
from
Denver, CO
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated: 10/3/2017
Horizons Clinical Research Center, LLC
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated:  10/3/2017
Moore Clinical Research Inc.
mi
from
Brandon, FL
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated: 10/3/2017
Moore Clinical Research Inc.
mi
from
Brandon, FL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated:  10/3/2017
Health Awareness
mi
from
Jupiter, FL
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated: 10/3/2017
Health Awareness
mi
from
Jupiter, FL
Click here to add this to my saved trials